ABBV vs HD: Which Is the Better Buy?
Side-by-side comparison of AbbVie Inc. and The Home Depot, Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-09-25.
AbbVie Inc. · Healthcare
$261.70
-1.0% upside to fair value
Med Conviction
Grade C
High Quality
VS
The Home Depot, Inc. · Consumer Cyclical
$292.18
+44.2% upside to fair value
Med Conviction
Grade B
High Quality
QuantHub Verdict
HD has more upside to fair value
(+44.2%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ABBV |
HD |
| Current Price |
$261.70 |
$292.18 |
| Fair Value Estimate |
$259.04 |
$421.26 |
| Upside to Fair Value |
-1.0%
|
+44.2%
|
| Market Cap |
$462.4B |
$291.3B |
| Forward P/E |
—
|
—
|
| EV / EBITDA |
24.8x
|
14.7x
|
| Price / Sales |
7.2x
|
1.7x
|
| Price / FCF |
23.6x
|
19.2x
|
| Revenue Growth YoY |
+10.2%
|
+5.7%
|
| Gross Margin |
71.5%
|
33.2%
|
| Operating Margin |
29.3%
|
12.4%
|
| Return on Equity |
-136.5%
|
102.7%
|
| Dividend Yield |
2.61% |
3.18% |
| FCF Yield |
4.25%
|
5.2%
|
| Analyst Consensus |
Strong Buy
|
Strong Buy
|
Investment Thesis
AbbVie is a diversified branded-biopharma company spanning immunology, neuroscience, oncology and aesthetics, with high-margin TTM economics including a 71.5% gross margin and 29.3% operating margin. Its successor immunology franchises are performing strongly: Q2 2026 revenue rose 10.2% year over year, with Skyrizi up 24.4% to $5.505 billion and Rinvoq up 24.5% to $2.525 billion, helping offset a…
The Home Depot is the largest home-improvement retailer in the United States, operating a network of roughly 2,300 stores supported by about 472,400 full-time employees, and serving both do-it-yourself homeowners and professional contractors through stores, homedepot.com, and specialty sites such as blinds.com. The business quality is high: it generates a 102.7% return on equity, a 33.2% trailing…
Accumulation Zones
| Metric |
ABBV |
HD |
| Zone Low |
$194.28 |
$315.94 |
| Zone High |
$220.18 |
$358.07 |
| In Buy Zone? |
No
|
Yes
|